Yarrow Bioscience (NASDAQ:YARW) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Yarrow Bioscience (NASDAQ:YARW) to a hold rating in a report released on Saturday morning.

Several other research analysts have also recently commented on YARW. BTIG Research began coverage on Yarrow Bioscience in a research note on Monday, August 3rd. They set a “buy” rating and a $58.00 target price for the company. TD Cowen initiated coverage on Yarrow Bioscience in a research report on Tuesday, July 28th. They issued a “buy” rating on the stock. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $58.00.

Yarrow Bioscience Stock Performance

Shares of NASDAQ YARW opened at $36.42 on Friday. The firm has a market capitalization of $97.24 million, a PE ratio of -2.49 and a beta of 1.96. Yarrow Bioscience has a 12-month low of $14.02 and a 12-month high of $46.95.

About Yarrow Bioscience

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.